More Neuroscientific Biopharmaceuticals Ltd. news
Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

NSB - Breakthrough results from Spinal Cord Injury Model

Jul 2, 2019 at 12:17 AM EDT · Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · Jul 2, 2019 at 12:17 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/nsb-breakthrough-results-from-spinal-cord-injury-model

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Earlier from Neuroscientific Biopharmaceuticals

  • Appendix 4D & Half-Year Financial StatementsFeb 25, 2019
  • Non-Renounceable Issue ProspectusNov 9, 2018
  • NSB Research CollaborationSep 20, 2018
  • NSB - Contract Research AgreementSep 6, 2018
  • Pause In TradingSep 5, 2018

Later from Neuroscientific Biopharmaceuticals

  • NSB - FInal Data Received from Spinal Cord Injury ModelJul 31, 2019
  • NSB Receives R&D Advanced Overseas FindingSep 1, 2019
  • EmtinB Can Become a Revolutionary Treatment for GlaucomaSep 30, 2019
  • AGM AddressNov 28, 2019
  • NSB - Company UpdateDec 1, 2019
All Neuroscientific Biopharmaceuticals news releases↗

Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.

Follow Neuroscientific Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer